Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Down 52% After Hours on Interim Covid-19 Vaccine Study Data

06/16/2021 | 03:40pm EDT

By Josh Beckerman

CureVac NV shares fell 52% to $45.45 in after-hours trading as the company reported unfavorable interim data from a Covid-19 vaccine clinical trial.

"In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said.

The HERALD study, conducted by CureVac in conjunction with Bayer, enrolled about 40,000 people in 10 countries in Latin America and Europe.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

06-16-21 1740ET

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.44% 50.51 Delayed Quote.4.43%
CUREVAC N.V. 0.79% 49.57 Delayed Quote.-39.24%
All news about CUREVAC N.V.
07/20EU begins real-time review of Sanofi-GSK COVID-19 vaccine
RE
07/05S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/04S.Korea in talks with mRNA vaccine makers to make up to 1 bln doses -govt off..
RE
07/01AFTER HOURS WATCH LIST SCORECARD : Usws, cvac
MT
07/01SECTOR UPDATE : Health Care Stocks Post Solid Gains Thursday
MT
07/01SECTOR UPDATE : Health Care Stocks Outpacing Most Other Sectors This Afternoon
MT
07/01GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac...
07/01SECTOR UPDATE : Health Care Stocks Steady Premarket Thursday
MT
07/01Wall Street Sees Narrowly Mixed Open; Weekly Jobless Claims Fall
MT
07/01EUROPEAN MIDDAY BRIEFING : Stocks Jump to Open -2-
DJ
More news
Financials
Sales 2021 486 M 577 M 577 M
Net income 2021 341 M 404 M 404 M
Net cash 2021 2 745 M 3 260 M 3 260 M
P/E ratio 2021 14,8x
Yield 2021 -
Capitalization 18 113 M 21 497 M 21 510 M
EV / Sales 2021 31,6x
EV / Sales 2022 3,05x
Nbr of Employees 505
Free-Float 44,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 41,51 €
Average target price 63,03 €
Spread / Average Target 51,9%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-39.24%21 497
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-12.42%27 907